R. Gregory Bociek, M.D.
Associate Professor, Internal Medicine
Division of Hematology & Oncology
UNMC Oncology/Hematology Division
987680 Nerbaska Medical Center
Omaha, NE 681980-7680
Main practice location:
Peggy D. Cowdery Patient Care Center
Lied Transplant Center
987835 Nebraska Medical Center
Omaha, NE 68198-7835
Cancer Center at Village Pointe
111 North 175th Street
Omaha, NE 68118
Sep. 1982-June 1984: B. Sc. Biology, Queen's University, Kingston, Ontario, Canada
Sep. 1984-May 1988: Medical Degree, University of Ottawa
July 1988-June 1991: Residency, Internal Medicine, University of Ottawa
July 1991-June 1993: Fellowship, Medical Oncology,
July 1991-June 1993: Chief Resident, Medical Oncology, University of Ottawa
July 1993-June 1994: Fellowship, Bone Marrow Transplantation, University of Nebraska Medical Center
Sep. 1994-June 1996: Clinical Scholar, University of Ottawa
June 1999: Masters in Clinical Epidemiology of Science, University of Ottawa
The Nebraska Medical Center
Dr. Bociek is an Associate Professor and has been on faculty at UNMC since 1998. Dr. Bociek completed his residency and fellowship training in oncology at the University of Ottawa and bone marrow transplantation training at the University of Nebraska Medical Center. He also completed a master degree in Clinical Epidemiology. Dr. Bociek's expertise is in the treatment of patients with lymphoma. Dr. Bociek is the current Program Director of Hematology/Oncology Fellowship Program at UNMC. Dr. Bociek is involved in various clinical trials in patients with lymphoma. He enjoys interacting with students and is involved in various research activities at UNMC. He reviews for various journals in hematology and oncology.
Vose JM, Bierman PJ, Enke C, Hankins J, Bociek G, Lynch JC, Armitage JO. Phase I Trial of Iodine-131 Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Non-Hodgkin’s Lymphoma. J of Clin Onc 2004. Jan;23(3): 461-467.
Ganti AK, Weisenburger DD, Smith LM, Hans CP, Bociek RG, Bierman PJ, Vose JM and Armitage JO. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: The Nebraska LymphomaStudy Group Experience. Ann Oncol.: 2006
Ganti AK, Bociek RG, Bierman PJ, Enke CA, Vose JM, Armitage JO. Follicular lymphoma: expanding therapeutic options.
Oncology 2005 Feb; V19(2), pp 213-28; discussion 228, 233-6, 239.
Vose JM, Bierman PJ, Enke CA, Hankins J, Bociek G, Lynch JC, Armitage JO. Phase II Trial of Iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin’s lymphoma. J Clin Oncol 2005 Jan 20; V23(3), pp 461-7.
Bociek RG. Adult Burkitt’s Lymphoma. Clin Lymphoma 2005 Jun; V6(1), pp. 11-20.
Hans CP, Weisenburger DD, Chan WC, Aoun P, Cochran GT, Pan Z, Smith LM, Lynch JC, Bociek RG, Bierman PJ, Vose JM, Armitage JO and Greiner TC. Expression of PKC-Beta or Cyclin D2 Predicts for Inferior Survival in Diffuse Large B-Cell Lymphoma. Mod Pathol 2005 Oct; V18, pp 1377-84.
Armitage JO, Bierman PJ, Bociek RG, Vose JM: Lymphoma 2006: Classification and Treatment. Oncology (Williston Park). 20:231-9; discussion 242, 244, 249. 2006.
Ganti AK, Weisenburger DD, Smith LM, Hans CP, Bociek RG, Bierman PJ, Vose J and Armitage JO. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. Ann Oncol: 2006.
O’Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR. Randomized phase III trial of fludarabin plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2007 Mar 20; 25(9):1114-20.
Joshi AD, Dickinson JD, Hegde GV, Sanger WG, Armitage JO, Bierman PJ, Bociek RG, Devetten MP, Vose JM, Joshi SS. Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion. Cancer Genet Cytogenet. 2007 Jan 15;172(2):120-6.
Vose JM, Bierman PJ, Loberiza FR Jr, Bociek RG , Matso D, Armitage JO. Phase I Trial of 90Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin’s lymphoma following high-dose chemotherapy and autologous stem cell transplantation. Leukemia & Lymphoma, April 2007; 48(4): 683-690.
- Breast Cancer
Stem Cell Transplantation
- Thoracic Oncology
- Urologic Oncology
- Partners & Facilities